Alzheimer Disease Clinical Trials in Dallas, Texas

6 studies are recruiting for alzheimer disease in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

   This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P…

   Stage

   Phase 2

   Ages

   55 to 80

   Site

   Kerwin Research Center, LLC - Oak Cliff, Dallas, Texas

   Locations

   38 in total

   Run by

   Lighthouse Pharmaceuticals, Inc.

   See if you can join NCT06847321 on ClinicalTrials.gov

2. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Local Institution - 1260, Dallas, Texas

   Locations

   293 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

3. [18F]PI-2620 Phase 3 Histopathological Study

   This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after de…

   Stage

   Phase 3

   Ages

   50 and older

   Site

   Baylor Research Institute, Dallas, Texas

   Locations

   25 in total

   Run by

   Lantheus Biosciences Ltd.

   See if you can join NCT05641688 on ClinicalTrials.gov

4. Clinical Trial on Agitation in Alzheimer's Dementia

   The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

   Stage

   Phase 2

   Ages

   60 and older

   Site

   Baylor Scott and White Research Institute, Dallas, Texas

   Locations

   31 in total

   Run by

   IGC Pharma, LLC

   See if you can join NCT05543681 on ClinicalTrials.gov

5. Late Onset Alzheimer's Disease

   The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to…

   Stage

   Not phased

   Ages

   55 and older

   Site

   University of Texas Southwestern, Dallas, Texas

   Locations

   12 in total

   Run by

   Columbia University

   See if you can join NCT05010603 on ClinicalTrials.gov

6. ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

   The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

   Stage

   Not phased

   Ages

   50 to 85

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   10 in total

   Run by

   InSightec

   See if you can join NCT03671889 on ClinicalTrials.gov